๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hyderabad
Clinical trial register · India

Clinical Trials in Hyderabad

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
New Delhi 332 Mumbai 259 Hyderabad 237 Bangalore 193 Pune 189
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Asian Institute of Gastroenterology, India40 AstraZeneca35 Novartis Pharmaceuticals15 Bristol-Myers Squibb15 Eli Lilly and Company14
Site location
New Delhi332 Mumbai259 Hyderabad237 Bangalore193 Pune189
All 274 locations
Target enrolment
to
237 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200Atrial Fibrillation (AF)
Anthos Therapeutics, Inc.
Phase 3
2,500
Hyderabad, Kochi, Rudrapur, Ahmedabad, Ajmer, Bangalore, Bhubaneswar, Chandigarh
2022-12-27
Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Viral Lung Infection and Acute Respiratory Failure
AstraZeneca
Phase 3
3,527
Ahmedabad, Belagavi, Chennai, Dehradun, Gurgaon, Gurugram, Hyderabad, Kanpur
2022-12-13
Active, closed
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
NCT05648500Lupus Erythematosus, Systemic
Viatris Innovation GmbH
Phase 3
470
Ahmedabad, Bangalore, Chennai, Hyderabad, Jaipur, Nagpur, Nashik, Pune
2022-12-13
Active, closed
An RCT of Mycophenolate Mofetil (MMF) in Fibrotic Hypersensitivity Pneumonitis
NCT05626387Hypersensitivity Pneumonitis
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 4
144
Chandigarh, Hyderabad, Jaipur, Jodhpur, Lucknow, New Delhi, Rishikesh, Vellore
2022-11-23
Active, closed
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
NCT05611671Inflammatory Bowel Diseases, Colitis, Ulcerative
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
280
Gurgaon, Hyderabad, Jaipur, Ludhiana, New Delhi, Noida, Secunderabad, Surat
2022-11-21
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
Eli Lilly and Company
Phase 3
15,374
Ahmedabad, Bikaner, Hyderabad, Lucknow, Ludhiana, Mumbai, Nagpur, New Delhi
2022-10-11
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
Eli Lilly and Company
Phase 3
8,000
Ahmedabad, Bangalore, Belagavi, Bhubaneswar, Chandigarh, Chennai, Hyderabad, Kanpur
2022-10-04
Recruiting
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
NCT05283226Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
NATCO Pharma Ltd.
Phase 2
21
Mumbai, Pune, Hyderabad
2022-09-30
Active, closed
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05528510Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
418
Gurugram, Hyderabad, Manipal, Mumbai, Surat
2022-09-13
Recruiting
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
NCT05511363Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
410
Ahmedabad, New Delhi, Hyderabad
2022-08-23
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289Lupus Nephritis
Novartis Pharmaceuticals
Phase 2
240
Ahmedabad, Kozhikode, New Delhi, Vellore, Hyderabad, Lucknow, Puducherry
2022-08-10
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
Janssen Research & Development, LLC
Phase 2
703
Ahmedabad, Bengaluru, Bhubaneswar, Chennai, Gurgaon, Hyderabad, Mumbai, New Delhi
2022-07-22
Active, closed
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05321420Idiopathic Pulmonary Fibrosis
PureTech
Phase 2
240
Vadodara, Bengaluru, Aurangabad, Nagpur, Hyderabad, Kanpur, Kolkata, Belagฤve
2022-07-22
Active, closed
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997Multiple Myeloma
Celgene
Phase 3
939
Hyderabad, Bangalore, Ernฤkulam, Mumbai, Kolkata, Puducherry
2022-06-23
By invitation
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
NCT05248659Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Hyderabad, Ahmedabad, Nadiฤd, Bengaluru, Manipal, Kozhikode, Thiruvananthapuram, Pune
2022-04-05
Active, closed
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842Hepatocellular Carcinoma
AstraZeneca
Phase 3
760
Ahmedabad, Bangalore, Delhi, Hyderabad, Jaipur, Kolkata, Mumbai, New Delhi
2022-03-28
Active, closed
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
791
Ahmedabad, Bangalore, Delhi, Howrah, Hyderabad, Jaipur, Kolkata, Marg Jaipur
2022-02-18
Active, closed
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133Lupus Nephritis
AstraZeneca
Phase 3
363
Ahmedabad, Dehradun, Delhi, Hyderabad, Kolkata, Nadiฤd, Pune, Secunderabad
2022-02-15
Active, closed
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
NCT04954859Hepatitis B
GlaxoSmithKline
Phase 2
360
Belagavi, Coimbatore, Hyderabad, Kanchan Bagh Hyderabad, Mumbai, New Delhi, Pune, Surat
2021-12-14
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
NCT05156281Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,007
Kochi, Pune, New Delhi, Amritsar, Hyderabad, Lucknow, Kolkata
2021-12-13
Active, closed
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
Jazz Pharmaceuticals
Phase 3
920
Bhubaneswar, Gurgaon, Hyderabad, New Delhi, Patna, Vijayawada
2021-12-02
Active, closed
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
17,004
Guntur, Hyderabad, Ahmedabad, Vadodara, Belagavi, Manipal, Mysore, Kochi
2021-11-23
Active, closed
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
454
Bangalore, Delhi, Hyderabad, Mumbai, Nashik
2021-10-28
Active, closed
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
NCT05104866Breast Cancer
AstraZeneca
Phase 3
732
Gurgaon, Howrah, Hyderabad, Jaipur, Kolkata, Nashik, Surat, Visakhapatnam
2021-10-18
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
874
Bangalore, Thiruvananthapuram, Mumbai, Nagpur, Nashik, Pune, Hyderabad
2021-10-04
Rows per page Showing 176–200 of 237
Previous 6 7 8 9 10 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/hyderabad

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.